Interestingly, second-generation CB1 blockers now provide safer alternatives to previous and highly brain-penetrant agents for the treatment of metabolic disorders, including diabetes, obesity, and weight loss with better psychiatric tolerability (Gueye et al., 2016). This evidence concerns the gene CNR1 and Obesity.